Clinical Trials Browser

INDUSTRY × Has results × AZD 6244 × Clear all

NCT04924608 2026-01-12

KOMET

Phase 3 Active not recruiting

145 enrolled 17 charts 1 FDA

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05309668 2025-12-18

SPRINKLE

Phase 1/2 Active not recruiting

36 enrolled 37 charts

Neurofibromatosis 1

NCT03833427 2024-11-07

MK-5618-001

Phase 1 Terminated

32 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03745989 2023-07-27

MK-8353-014

Phase 1 Completed

30 enrolled 19 charts

Neoplasm Metastasis

NCT01843062 2019-08-28

ASTRA

Phase 3 Terminated

233 enrolled 14 charts

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT01021748 2018-08-07

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Phase 1 Completed

63 enrolled 17 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT00890825 2018-06-20

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

Phase 2 Completed

88 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT01605916 2016-10-21

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

Phase 1 Completed

33 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02322749 2016-08-31

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

Phase 1 Completed

48 enrolled 16 charts

Neoplasms

NCT02063230 2016-07-21

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

Phase 1 Completed

32 enrolled 12 charts

Other solid neoplasm

Solid Tumors

NCT01949870 2016-05-13

Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study

Phase 1 Terminated

6 enrolled 6 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT02238782 2016-04-05

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

Phase 1 Completed

21 enrolled 4 charts

Neoplasms

NCT00936221 2016-03-14

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Phase 2 Completed

385 enrolled 11 charts

Melanoma

NCT02056392 2015-11-09

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

Phase 1 Completed

54 enrolled 31 charts

Other solid neoplasm

Solid Tumours